A recently published study of 2017 data found that 60% of residential treatment centers in the U.S. offered zero medications for opioid use disorder and just 15% of patients had an MOUD as part of their treatment plan.
In a study of OUD patients following their transition from two Phase 3 clinical trials of Sublocade, 44% of participants self-reported sustained illicit opioid-free weeks for the duration of the project.
Marc Fishman, MD, of Maryland Treatment Centers and the Johns Hopkins University School of Medicine, discusses new formulations of medicines to treat OUD and delivery strategies during the COVID-19 pandemic.
In a study of mice, a synthetic molecule was found to reduce cocaine and methamphetamine consumption and cravings without the side effects typically associated with other interventions, according to research published Thursday in the journal Cell.
Researchers at Temple University have received a $1.77 million grant from the National Institute on Drug Abuse to study the effects of a therapy for the treatment of cocaine use disorder, according to a media report.
With the far reach of the opioid epidemic and the high comorbidity of opioid addiction with other psychiatric disorders, the session will be relevant to all attendees, not just those in addiction medicine.
During the opening plenary of NCAD West on Thursday, Colorado Consortium for Prescription Drug Abuse director Rober Valuck, PhD, RPh, FNAP, implored attendees to aggressively fight barriers to treatment, scrutinize their own work, and learn from their peers.
Las Vegas Recovery Center chief medical officer Mel Pohl, MD, DFASAM, shared risks of using opioids to treat chronic pain and offered non-medication alternatives to improve patients’ ability to function on Thursday at NCAD West.
SAN DIEGO—The opioid withdrawal drug lofexidine demonstrated statistically significant efficacy across a half-dozen patient- and clinician-reported outcomes during the first 7 days after immediate opioid cessation, according to study presented at…